Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | TMEM97 | Q5BJF2 | 11/20 | 0.45 |
| ▸ | SIGMAR1 | Q99720 | 11/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | PTGDR2 | Q9Y5Y4 | 5/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6493228 | 0.89 | PTGDR2 (0.47) | MEN1KMT2ATMEM97SIGMAR1NPSR1 | |
| SCHEMBL6485348 | 0.87 | MEN1 (0.49) | MEN1KMT2ATMEM97SIGMAR1NPSR1 | |
| SCHEMBL6490814 | 0.85 | MEN1 (0.47) | MEN1KMT2ATMEM97SIGMAR1NPSR1 | |
| SCHEMBL6483800 | 0.76 | MEN1 (0.47) | MEN1KMT2ANPSR1SMN1; SMN2NPC1 | |
| SCHEMBL6492696 | 0.76 | PTGDR2 (0.47) | MEN1KMT2ANPSR1SMN1; SMN2NPC1 | |
| SCHEMBL6494502 | 0.76 | TMEM97 (0.49) | MEN1KMT2ATMEM97SIGMAR1NPSR1 | |
| SCHEMBL6483674 | 0.74 | SMN1; SMN2 (0.48) | MEN1KMT2ATMEM97SIGMAR1NPSR1 | |
| SCHEMBL6491970 | 0.74 | MEN1 (0.48) | MEN1KMT2ANPSR1SMN1; SMN2NPC1 | |
| SCHEMBL6492896 | 0.74 | PTGDR2 (0.50) | MEN1KMT2ANPSR1PTGDR2 | |
| SCHEMBL21996394 | 0.73 | TMEM97 (0.57) | MEN1KMT2ATMEM97SIGMAR1NPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050282796-A1 | Tetracyclic azepinoindole compounds | PFIZER | 2005-12-22 | — | — | US | claimed |
| EP-1173440-B1 | TETRACYCLIC AZEPINOINDOLE COMPOUNDS AS 5-HT RECEPTOR LIGANDS | UPJOHN CO (US) | 2004-09-15 | — | — | EP | claimed |
| US-20050282796-A1 | Tetracyclic azepinoindole compounds | PFIZER | 2005-12-22 | — | — | US | disclosed |
| US-6875762-B2 | Tetracyclic azepinoindole compounds | PFIZER (US) | 2005-04-05 | — | — | US | disclosed |
| EP-1173440-B1 | TETRACYCLIC AZEPINOINDOLE COMPOUNDS AS 5-HT RECEPTOR LIGANDS | UPJOHN CO (US) | 2004-09-15 | — | — | EP | disclosed |
| US-20040138202-A1 | Tetracyclic azepinoindole compounds | PHARMACIA AND UPJOHN COMPANY | 2004-07-15 | — | — | US | disclosed |
| US-6407092-B1 | 5-HYDROXYTRYPTAMINE MODULATORS AND ANTISEROTONINE AGENTS; TREATING EATING, SEXUAL, SLEEP, NERVOUS SYSTEM, PSYCHOLOGICAL, AND GASTROINTESTINAL DISORDERS; ANTIDEPRESSANTS, ANXIOLYTIC AGENTS | PHARMACIA & UPJOHN COMPANY | 2002-06-18 | — | — | US | disclosed |
| EP-1173440-A1 | TETRACYCLIC AZEPINOINDOLE COMPOUNDS AS 5-HT RECEPTOR LIGANDS | PHARMACIA & UPJOHN COMPANY (US) | 2002-01-23 | — | — | EP | disclosed |
| WO-2000064899-A1 | TETRACYCLIC AZEPINOINDOLE COMPOUNDS AS 5-HT RECEPTOR LIGANDS | PHARMACIA & UPJOHN COMPANY (US) | 2000-11-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050282796-A1 | Tetracyclic azepinoindole compounds | TBXA2R, NPY5R, AZI2 | MEN1 242/4885KMT2A 2440/4885MAPK1 4321/4885 |
| US-20040138202-A1 | Tetracyclic azepinoindole compounds | TPH1, AZI2, CYP1A2 | MEN1 164/4885KMT2A 2669/4885MAPK1 3137/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.